Filizoglu, N. Et Al. 2022. F-18-FDG PET/CT Metabolic Response With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Treated With Cyclin-Dependent 4/6 Kinase Inhibitors. CLINICAL NUCLEAR MEDICINE , vol.47, no.9 .

Filizoglu, N., Ozguven, S., & Erdil, T. Y., (2022). F-18-FDG PET/CT Metabolic Response With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Treated With Cyclin-Dependent 4/6 Kinase Inhibitors. CLINICAL NUCLEAR MEDICINE , vol.47, no.9.

Filizoglu, NUH, SALİH ÖZGÜVEN, And TANJU YUSUF ERDİL. "F-18-FDG PET/CT Metabolic Response With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Treated With Cyclin-Dependent 4/6 Kinase Inhibitors," CLINICAL NUCLEAR MEDICINE , vol.47, no.9, 2022

Filizoglu, NUH Et Al. "F-18-FDG PET/CT Metabolic Response With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Treated With Cyclin-Dependent 4/6 Kinase Inhibitors." CLINICAL NUCLEAR MEDICINE , vol.47, no.9, 2022

Filizoglu, N. Ozguven, S. And Erdil, T. Y. (2022) . "F-18-FDG PET/CT Metabolic Response With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Treated With Cyclin-Dependent 4/6 Kinase Inhibitors." CLINICAL NUCLEAR MEDICINE , vol.47, no.9.

@article{article, author={NUH FİLİZOĞLU Et Al. }, title={F-18-FDG PET/CT Metabolic Response With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Treated With Cyclin-Dependent 4/6 Kinase Inhibitors}, journal={CLINICAL NUCLEAR MEDICINE}, year=2022}